Immunological differences between primary and metastatic breast cancer
Top Cited Papers
- 10 September 2018
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 29 (11), 2232-2239
- https://doi.org/10.1093/annonc/mdy399
Abstract
Little is known about how the immune microenvironment of breast cancer evolves during disease progression. We compared tumor infiltrating lymphocyte (TIL) count, PD-L1 protein expression by immunohistochemistry and mRNA levels of 730 immune-related genes using Nanostring technology in primary and metastatic cancer samples. TIL counts and PD-L1 positivity were significantly lower in metastases. Immune cell metagenes corresponding to CD8, T-helper, T-reg, Cytotoxic T, Dendritic and Mastoid cells, and expression of 13 of 29 immuno-oncology therapeutic targets in clinical development including PD1, PD-L1, and CTLA4 were significantly lower in metastases. There was also coordinated down regulation of chemoattractant ligand/receptor pairs (CCL19/CCR7, CXCL9/CXCR3, IL15/IL15R), interferon regulated genes (STAT1, IRF-1,-4,-7, IFI-27,-35), granzyme/granulysin, MHC class I and immune proteasome (PSMB-8,-9,-10) expression in metastases. Immunotherapy response predictive signatures were also lower. The expression of macrophage markers (CD163, CCL2/CCR2, CSF1/CSFR1, CXCR4/CXCL12), pro-tumorigenic toll like receptor pathway genes (CD14/TLR-1,-2,-4,-5,-6/MyD88), HLA-E, ecto-nuclease CD73/NT5E and inhibitory complement receptors (CD-59,-55,-46) remained high in metastases and represent potential therapeutic targets. Metastatic breast cancers are immunologically more inert than the corresponding primary tumors but some immune-oncology targets and macrophage and angiogenesis signatures show preserved expression and suggest therapeutic combinations for clinical testing.Keywords
Funding Information
- Breast Cancer Research Foundation
- Susan Komen Foundation for the Cure (LP, SAC160076)
- Department of Defense Breast Cancer Research Program Awards (W81XWH-15-1-0117)
- Rosztoczy Foundation
This publication has 30 references indexed in Scilit:
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199Journal of Clinical Oncology, 2014
- The Yin and Yang of Toll-like receptors in cancerOncogene, 2013
- Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive SignaturesPLOS ONE, 2011
- Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast CancerJNCI Journal of the National Cancer Institute, 2010
- Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative CancersJournal of Clinical Oncology, 2010
- CD73: A Novel Target for Cancer ImmunotherapyCancer Research, 2010
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2010
- T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancersBreast Cancer Research, 2009
- The complex biology of autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligaseMolecular BioSystems, 2009
- Immune-refractory cancers and their little helpers—An extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?Seminars in Cancer Biology, 2007